General information

James Schurr, PharmD

Osmosis Faculty Reviewer

Dr. James Schurr (PharmD) is a medical student at the Stony Brook University Renaissance School of Medicine in Long Island, New York and a critical care pharmacist board certified in pharmacotherapy. He holds a PharmD degree from St. John’s University where he led the first team in St. John’s history to the national finals of the American College of Clinical Pharmacy’s Clinical Pharmacy Challenge. After pharmacy school, James completed a PGY-1 pharmacy practice residency and a PGY-2 specialty residency in critical care at the Brigham and Women’s Hospital in Boston, Massachusetts. James brings his critical care experience and pharmacist-to-medical student perspective to the Osmosis team to make sure learners are getting the highest quality pharmacology education. When he is not rounding on the hospital floors or reviewing Osmosis pharmacology content, you can find James at home or on a drive in his Jeep with his wife and their pet Corgi.


  • Schurr, J. W., Seifert, F. C., & McLarty, A. J. (2019). Long-term discontinuation of antithrombotic therapy in patients with HeartMate II continuous-flow left ventricular assist device support. The International Journal of Artificial Organs, 42(12), 770-774. doi:10.1177/0391398819861976
  • Schurr, J. W., Muske, A., Stevens, C. A., Culbreth, S. E., Sylvester, K. W., & Connors, J. M. (2019). Derivation and validation of age- and body mass index-adjusted weight-based unfractionated heparin dosing. Clinical and Applied Thrombosis/Hemostasis, 25. doi:10.1177/1076029619833480
  • Ting, C., Sylvester, K. W., & Schurr, J. W. (2018). Time in the therapeutic range for assessing anticoagulation quality in patients receiving continuous unfractionated heparin. Clinical and Applied Thrombosis/Hemostasis, 24(9), 178S-181S. doi:10.1177/1076029618798944
  • Kovacevic, M. P., Schurr, J. W., & Dell'Orfano, H. (2018). Accuracy of medication safety report severity level among disciplines at a tertiary academic medical center. Current Emergency and Hospital Medicine Reports, 6, 116-119. doi:10.1007/s40138-018-0165-6
  • Schurr, J. W., Stevens, C. A., Bane, A., Culbreth, S. E., Miller, A. L., Connors, J. M., & Sylvester, K. W. (2018). Evaluation of compliance with a weight-based nurse-driven heparin nomogram in a tertiary academic medical center. Critical Pathways in Cardiology, 17(2), 83-87. doi:10.1097/HPC.0000000000000113
  • Schurr, J. W., Stevens, C. A., Bane, A., Luppi, C., Culbreth, S. E., Miller, A. L., ... Sylvester, K. W. (2018). Description and evaluation of the implementation of a weight-based, nurse-driven heparin nomogram in a tertiary academic medical center. Clinical and Applied Thrombosis/Hemostasis, 24(2), 248-253. doi:10.1177/1076029617721009
  • Schurr, J. W., Szumita, P. M., & DeGrado, J. R. (2017). Neuroendocrine derangements in early septic shock: Pharmacotherapy for relative adrenal and vasopressin insufficiency. Shock, 48(3), 284-293. doi:10.1097/SHK.0000000000000864
  • Schurr, J. W., Stevens, C. A., & Mehra, M. R. (2017). An ACE in the hole: Unraveling gastrointestinal bleeding in left ventricular assist systems. The Journal of Heart and Lung Transplantation, 36(4), P373-P375. doi:10.1016/j.healun.2017.01.1298
  • Rocchio, M. A., Schurr, J. W., Hussey, A. P., & Szumita, P. M. (2017). Intravenous immune globulin stewardship program at a tertiary academic medical center. The Annals of Pharmacotherapy, 51(2), 135-139. doi:10.1177/1060028016673071
  • Schurr, J. W., Wu, W., Smith-Hannah, A., Smith, C. J., & Barrera, R. (2016). Incidence of sepsis and mortality with prior exposure of HMG-COA reductase inhibitors in a surgical intensive care population. Shock, 45(1), 10-15. doi:10.1097/SHK.0000000000000484
  • Schurr, J. W., Gitman, B., & Belchikov, Y. (2014). Controversial therapeutics: The β-adrenergic antagonist and cocaine-associated cardiovascular complications dilemma. Pharmacotherapy, 34(12), 1269-1281. doi:10.1002/phar.1486
  • Schurr, J., Gao, D., Leibfried, M., & Cassagnol, M. (2013). Conventional and investigational treatment options for PAH. U.S. Pharmacist, 38(7), HS3-HS8.